Cash-Strong Vical Narrows Focus To Two Lead Programs
This article was originally published in The Pink Sheet Daily
Executive Summary
Wary of current financial environment, biotech is bullish on early pipeline projects but will await partners to advance them.
You may also be interested in...
Vical Joins Forces With Astellas On CMV Vaccine
Vaccine-focused biotech Vical Inc. announced July 14 that it has inked a global licensing agreement with Japan's Astellas Pharma Inc. to develop and commercialize the biotech's cytomegalovirus (CMV) vaccine, TransVax
Vical Joins Forces With Astellas On CMV Vaccine
Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.
Vical Joins Forces With Astellas On CMV Vaccine
Astellas will take over the development of TransVax and pay Vical $103 million plus royalties.